Report Overview

The Brazil Brain Cancer drugs market size stood at USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Brain cancer is a disease of the brain in which cancer cells (malignant cells) arise in the brain tissue (cancer of the brain). Cancer cells grow to form a mass of cancer tissue (tumour) that interferes with brain functions such as muscle control, sensation, memory, and other normal body functions. Tumours composed of cancer cells are called malignant tumours, and those composed of mainly noncancerous cells are called benign tumours. Cancer cells that develop from brain tissue are called primary brain tumours while tumours that spread from other body sites to the brain are termed metastatic or secondary brain tumours.



Market Drivers

Rapidly increasing prevalence of neurological disorders are identified in adults and children is augmenting the market growth. Brain disorders, which comprise an amalgamation of psychiatric, developmental, and neurodegenerative diseases, are a rising cause of morbidity. This can largely be attributed to the increasing geriatric population.

Thus, the rising incidence of these neurological disorders is the major factor propelling the brain tumour drugs market growth. Research and development to provide advanced patient care for brain disorders are accelerating. Innovative experiments leading to combination therapies with new or existing drug molecules have led to a rise in the number of pipeline candidates for brain tumour drugs.